Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus aureus through Domain Shuffling

28 May 2021

Abstract excerpt

The increase in the prevalence of multidrug-resistant (MDR) Staphylococcus aureus with strong biofilm-forming capacity poses a serious public health concern. Endolysins derived from bacteriophages are a promising solution for antibiotic resistance problems. However, some natural staphylococcal endolysins have several shortcomings, such as low solubility and high sequence homology among domains. To overcome these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Resistance in Staphylococcus
Share to Bacteriophages and microbial interactions
Share to Probiotics and Fermented Foods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34047546
DOI: 10.1021/acsinfecdis.0c00812

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus aureus through Domain ShufflingPMID 34047546Read ↗

Uncovering novel endolysins against methicillin-resistant <i>Staphylococcus aureus</i> using microbial single-cell genome sequencingSemantic proximity Read ↗

Novel Chimerical Endolysins with Broad Antimicrobial Activity Against Methicillin-Resistant <i>Staphylococcus aureus</i>Semantic proximity Read ↗

Fusion with a cell wall binding domain renders autolysin LytM a potent anti-Staphylococcus aureus agentSemantic proximity Read ↗

Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus ?Semantic proximity Read ↗

Bacteriophage St_134 and its Endolysin as a Potential Staphylococcus Biofilm-Removing Biological AgentSemantic proximity Read ↗

Phage-Encoded EndolysinsSemantic proximity Read ↗

MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infectionsSemantic proximity Read ↗

A novel chimeric endolysin with enhanced lytic and binding activity against Clostridium perfringensSemantic proximity Read ↗

The New SH3b_T Domain Increases the Structural and Functional Variability Among SH3b-Like CBDs from Staphylococcal Phage EndolysinsSemantic proximity Read ↗

<b> A novel enterococcus phage endolysin Lys22 with a wide host range against mixed biofilm of <i>Enterococcus faecalis</i> , <i>Staphylococcus aureus</i> and <i>Acinetobacter baumannii</i> </b>Semantic proximity Read ↗

Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinitySemantic proximity Read ↗

Bacteriophage endolysins — extending their application to tissues and the bloodstreamSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.